Recently, a preclinical evaluation of GB1107 and TD139, inhibitors of Gal-3, revealed promising outcomes in the treatment and prevention of the metastatic spread of thyroid cancer [94]. This evidence concerns the gene LGALS3 and thyroid cancer.